dr. portnoy on the importance of driver mutations in the treatment of nsclc
Published 6 years ago • 97 plays • Length 1:40Download video MP4
Download video MP3
Similar videos
-
6:04
the future of driver mutations in nsclc
-
1:14
dr. brahmer on targeting driver mutations in nsclc
-
1:06
dr. garon discusses driver mutations in sclc
-
3:44
what is a driver mutation?
-
0:53
dr. kris discusses driver mutations test false negatives
-
6:12
braf as a driver in melanoma
-
19:44
driverank: discovering patient-specific driver mutations
-
2:15
dr. redner on the potency of gilteritinib in aml
-
40:25
oncogenomics: the driver of clinical utility
-
56:02
cancer genomics – a driver for transforming diagnosis and treatment of prostate cancer: dr baichoo
-
1:26
dr. nathan on long-term outcomes with dabrafenib/trametinib in braf v600-mutant melanoma
-
47:41
cancer and biophotonics
-
6:47
how liquid biopsies help understanding of resistance to chemotherapy
-
1:46
dr. nathan on 5-year survival outcomes of combi-d and combi-v trials in braf v600-mutant melanoma
-
27:03
triple negative breast cancer: predictive and prognostic biomarkers for neo/adjuvant therapy
-
1:09
prevalence of patients with non-driver nsclc
-
2:06
dr. bryce on potential biomarkers of response to immunotherapy in prostate cancer
-
0:52
dr. offin on potential implications of introducing biosimilars into oncology
-
0:50
new findings on the utility of circulating biomarkers for liquid biopsy